Engineered Microparticles for Treatment of Murine Brain Metastasis by Reprograming Tumor Microenvironment and Inhibiting MAPK Pathway

Abstract

Abstract Brain metastases (BRM) are common in advanced lung cancer. However, their treatment is challenging due to the blood‐brain barrier (BBB) and the immunosuppressive tumor microenvironment (ITME). Microparticles (MPs), a type of extracellular vesicle, can serve as biocompatible drug delivery vehicles that can be further modulated with genetic engineering techniques. MPs prepared from cells induced with different insults are compared and it is found that radiation‐treated cell‐released microparticles (RMPs) achieve optimal targeting and macrophage activation. The enzyme ubiquitin‐specific protease 7 (USP7), which simultaneously regulates tumor growth and reprograms M2 macrophages (M2Φ), is found to be expressed in BRM. Engineered RMPs are then constructed that comprise: 1) the RMP carrier that targets and reprograms M2Φ; 2) a genetically expressed SR‐B1‐targeting peptide for improved BBB permeability; and 3) a USP7 inhibitor to kill tumor cells and reprogram M2Φ. These RMPs successfully cross the BBB and target M2Φ in vitro and in vivo in mice, effectively reprogramming M2Φ and improving survival in a murine BRM model. Therapeutic effects are further augmented when combined with immune checkpoint blockade. This study provides proof‐of‐concept for the use of genetically engineered MPs for the treatment of BRM.

Keywords

• blood‐brain barrier
• cancer immunotherapy
• extracellular vesicles
• macrophages polarization
• USP7